The present invention relates to a method for detecting and diagnosing Chlamydia suis infections in a subject, and a diagnostic kit therefor.

The present disclosure includes multiplexed systems, methods, devices, and kits for detecting status of one or more health conditions in a single device. It includes an extraction container for receiving a sample and extracting a target material from the sample; a testing container with at least a first and second well containing one or more buffers for receiving the extracted target material, and a signal output device including a housing containing two or more strips, each strip containing a) a loading zone; b) a reaction zone; c) a testing zone; and d) a control zone. The system and methods can be adapted for assessment of sexual health of one or more subjects, in relation to pregnancy, fertility, and/or sexually transmitted infections caused by one or more agents.

The invention provides methods for analyzing a patient's potential for achieving ongoing pregnancy with respect to a specific fertility treatment. The methods involve obtaining a sample containing microorganisms from an individual, identifying a number of specific microorganisms present in an individual, and comparing these microorganisms to those known to be associated with reproductive success. The individual is then informed of her or his potential reproductive success based upon the results of the comparison.

Methods are provided herein for determining the likelihood that a subject, such as an asymptomatic subject, has chlamydial pelvic inflammatory disease. In some embodiments, the method can determine the likelihood that a pharmaceutical agent is effective for treating a subject that has chlamydial pelvic inflammatory disease. In other specific non-limiting examples, the method predicts endometritis and elevated pathogen burden. The subject is a female, such as a human female.

In various embodiments devices and methods for the detection and/or quantification of clinically relevant pathogens (e.g., bacteria, fungi, viruses, etc.) are provided. In certain embodiments the device comprises a lateral-flow assay that detects the bacterium at a concentration of less than about 6?10.sup.6 cells/mL, less than about 3?10.sup.6 cells/ml, less than about 1?10.sup.6 CFU/mL, or less than about 50 ?g/mL. In certain embodiments the device comprises an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase solution; and a lateral-flow assay (LFA). In certain embodiments the device comprises a flow-through system comprising a concentration component comprising an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase solution; and a detection component disposed beneath said concentration component.

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.

The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.

The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

The present invention relates to a method and kit for detecting and diagnosing Chlamydia suis infections in a subject using peptides comprising the amino acid sequence of GTKDASID and/or SQQSSIAS as antigenic determinants.